Phase 2 N=62 Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users
Alcohol Abuse · Impulsive Behavior
Primary: Number of Drinks Consumed in a Laboratory Bar Session — 2.69; 2.96; 2.73; 2.39 drinks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 The ICON Study: Outcomes After FMT for Patients With IBD and CDI
Inflammatory Bowel Diseases · Clostridium Difficile Infection
Primary: Number of Participants With FMT Failure — 4 Participants
Phase 2 N=180 Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.6; 21.1 Months
Phase 2 N=40 A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
Lung Cancer
Primary: Change From Baseline in Percentage of Cells Staining Positive for Ki-67 in All Biopsy Specimens at Endpoint — 3.74; 6.15 percentage of cells with Ki-67 — p=0.556
Phase 2 N=35 A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Number of Treatment-emergent Adverse Events (TEAEs) — 2; 6; 4; 1 Participants
Phase 2 N=36 Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Hematological Malignancies · Acute Lymphoblastic Leukemia (ALL) · Acute Myeloid Leukemia (AML)
Primary: Engraftment — 94 percentage of patients
Phase 2 N=35 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Glioblastoma · Glioblastoma Multiforme · Gliosarcoma
Primary: Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With…
Phase 2 N=35 Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy
Epilepsy
Primary: Tmax Pharmacokinetic EndPoints — 1.000; 0.525 hours
Phase 2 N=7 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Bronchiolitis Obliterans · Constructive Bronchiolitis · Graft Versus Host Disease
Primary: Improvement in Lung Function - Increase in FEV1 — 0 Participants
Phase 2 N=144 Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Objective Response Rate (ORR) — 9.7; 6.9 percentage of participants — p=0.8
Phase 2 N=34 A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
Primary: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response (Complete Response (CR) + VGPR) — 50.0 percentage of participants
Phase 2 N=55 Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
Breast Cancer
Primary: Recommended Phase II Dose of Vorinostat in Combination With Weekly Paclitaxel/Trastuzumab — 300; 300 mg
Phase 2 N=48 Convalescent Plasma in the Treatment of COVID 19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) · COVID · Coronavirus
Primary: Mortality — 19 Participants
Phase 2 N=82 Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms
Alcohol Drinking
Primary: Alcohol Use — 29.59; 27.08 Percent of days
Phase 2 N=45 Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm · Neurotoxicity
Primary: Number of Participants With Adverse Events — 1; 13; 2; 1 Participants